The newly established ESR office in Brussels is located in the Domus Medica Europaea at the heart of the European quarter, within walking distance from the European Parliament and the European Commission. The Brussels office provides the ESR with a presence in the de facto ‘capital’ of the European Union to support its European affairs activities, in recognition of the great and growing importance of EU policy in areas like healthcare and research.
Address: Domus Medica Europaea, Rue de l´Industrie 24, 1040 Brussels, Belgium
Global Summit on Radiological Quality and Safety
The Global Summit on Radiological Quality and Safety (GSRQS) was conceived and developed by the European Society of Radiology (ESR) and the American College of Radiology (ACR) to provide a robust exchange of ideas, concerns and potential solutions to quality and safety issues in diagnostic radiology. It has been held biannually since 2013 bringing together experts from multiple organisations worldwide for a two-day summit dedicated to advancing the practice of diagnostic radiology.
ESR Launch Event of the 'European Action Plan for Medical Imaging'
The ESR Action Plan for Medical Imaging was launched at the European Parliament in Brussels on November 4, 2014 at an event hosted by Elisabeth Morin-Chartier, Quaestor of the European Parliament.
ESR-EAPM Roundtable on Radiology/Imaging
This roundtable event hosted by Biljana Borzan, MEP, on 'The role of Radiology/Imaging in Personalised Medicine: How to provide the right prevention and treatment to the right patient at the right time?' was held at the European Parliament, Brussels on October 15, 2013. It provided an insight into the crucial role of imaging in the era of personalised medicine, frequently undervalued by policy makers, and showcased the potential and needs of imaging research with regard to multi-disciplinary European collaboration in the context of Horizon 2020 in order to benefit Europe’s patients and to address the current societal challenges.
Located in London, the European Medicines Agency (EMA) is the EU regulatory body responsible for the scientific evaluation and supervision of medicines developed by pharmaceutical companies for use in the European Union.
The EMA collaborates with the national authorities of the 28 EU Member States plus Iceland, Norway and Liechtenstein, and has access to a pool of experts including regulators, academics, patients and healthcare professionals from across the EU.
Since 2013 the ESR has been a member of the EMA Healthcare Professionals Working Party (HCP WP), which contributes to the agency’s work including the harmonisation of SPC (summary of product characteristics), and the adaptive licensing project that aims at allowing early access to a new drug for patients with a niche indication.
The key objectives of the EMA include:
The ESR has been a member of the European Commission eHealth Stakeholder Group since its establishment in 2012. The group is composed of up to 30 European umbrella organisations and associations representing users (patients, professionals, providers, payers etc), industry, research, and standardisation bodies.
Policy areas of interest to the ESR include the Digital Agenda for Europe on eHealth and the eHealth Action Plan. The purpose of the group is to discuss and actively contribute to the development of EU eHealth policy in a multidisciplinary approach. In particular, it will contribute to the implementation of the eHealth Action Plan and the eHealth Network activities.
The European Commission Expert Group on Cancer Control was established in 2014 to provide better coordination of the different initiatives. The expert group, chaired by the Commission, assists in the drawing up of legal instruments and policy documents, guidelines and recommendations on cancer control. It consists of representatives from Member State national authorities as well as representatives from patient groups, scientific and medical associations, including the European Society of Radiology (ESR), organisations working on cancer prevention and industry.
Key objectives of the European Commission Expert Group on Cancer Control are:
Upcoming activities of the EC expert group include the establishment of a European Cancer Information System (ECIS), aiming to harmonise the existing national cancer registries and coordinating all the initiatives under the umbrella of the European Network of Cancer Registries (ENCR), the development of an ENCR website and establishment of dedicated ENCR working groups as well as the development of a common portal for data collection and software.
The EU Health Policy Platform is the European Commission's online platform to facilitate its contacts with health stakeholders. In addition to hosting formal EU expert groups like the eHealth Stakeholder Group (eHSG) or the Expert Group on Cancer Control, on which the ESR is represented, the HPP also serves as an open forum for healthstakeholders.
Each year, stakeholder organisations are given the opportunity to propose and lead thematic networks on healthcare issues. The thematic networks produce joint statements in cooperation with interested stakeholder organisations that are submitted to the European Commission and evaluated for potential follow-up actions to better reflect stakeholder priorities in EU policy.
ESR-led thematic network on medical training and professional development for patient safety
The 2017 thematic network on medical training and professional development for patient safety, led by ESR aims to raise awareness of the importance of harmonisation in medical education, promote evidence-based medicine to reduce variance and increase patient safety in medical practice through education & training; highlight the importance of continued medical education for high-quality healthcare utilising the latest research and technology and propose concrete actions in the area of education & training on the basis of existing EU policies.
The joint statement of the thematic network, currently endorsed by 15 organisations, was officially addopted at the annual EU Health Policy Platform meeting on November 27, 2017 in Brussels.